FinTech
Imugene: Progresses VAXINIA trial in December quarter
Imugene Progresses VAXINIA trial in December quarterImugene (IMU) has taken another step forward in its efforts to treat and eradicate tumours in cancer...
FinTech
Imugene: Receives VAXINIA ethics approval in Australia
Imugene Receives VAXINIA ethics approval in AustraliaImugene (IMU) receives Human Research Ethics Committee (HREC) approval to commence a phase one clinical trial of...
FinTech
Imugene: Presents fresh onCARlytics data at SITC annual meeting
Imugene Presents fresh onCARlytics data at SITC annual meetingImugene (IMU) presents new data for its onCARlytics oncolytic virus at the Annual Meeting of...
FinTech
Imugene: Generates income of $5.34m in H1 FY22
Imugene Generates income of $5.34m in H1 FY22Imugene (IMU) records an income of more than $5.34 million for the half-year ending December 31,...
Funding
Imugene: Receives $4.8M tax rebate on cancer research
Clinical-stage immuno-oncology company Imugene (IMU) has received a hefty tax rebate for its research and development (R&D) spending
The company has banked a...
FinTech
Imugene: Receives FDA approval for PD1-Vaxx trial
Imugene (IMU) has received approval from the U.S. Food and Drug Administration (FDA) to begin a clinical trial for its PD1-Vaxx drug
Then...
FinTech
Imugene: Receives key U.S. patent for cancer therapies
Imugene (IMU) shares are trading green today on news the healthcare stock was granted a core U.S. patent
The patent protects Imugene's B-Cell...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from up to 5 devices at once
Must read
